📊 MBOT Key Takeaways
Is Microbot Medical Inc. (MBOT) a Good Investment?
Microbot Medical is an early-stage medical device company with minimal revenue ($105K quarterly) and unsustainable cash burn (-$5.2M quarterly FCF), leaving only 3.7M in remaining cash—less than one quarter of runway. While the balance sheet shows $74.1M in equity with minimal debt, the 1.9% gross margin and -$4.3M operating losses demonstrate fundamental unprofitability with no clear near-term path to sustainability.
Microbot Medical remains effectively pre-revenue, with only $2.00K of revenue against a $13.14M net loss and negative free cash flow of $13.11M, indicating that current operations are not commercially self-sustaining. While the balance sheet shows low leverage and strong reported liquidity ratios, the absolute cash balance of $3.91M appears weak relative to annual cash burn, making funding risk a central fundamental concern. The core issue is not solvency today, but the lack of proven revenue scale, persistent operating losses, and poor growth quality.
Why Buy Microbot Medical Inc. Stock? MBOT Key Strengths
- Strong balance sheet with $74.1M stockholders equity and 0.03x debt-to-equity ratio
- Excellent liquidity position (22.59x current ratio) provides flexibility for immediate needs
- 100% year-over-year revenue growth demonstrates market demand and commercialization progress
- Low leverage provides capital cushion to execute business plan without imminent default risk
- Very low leverage with debt/equity of 0.03x and modest total liabilities relative to equity
- Strong reported current and quick ratios, indicating limited near-term balance sheet pressure from liabilities
- Net loss and EPS improved year over year, showing some reduction in loss intensity
MBOT Stock Risks: Microbot Medical Inc. Investment Risks
- Critical cash runway of less than one quarter given -$5.2M quarterly free cash flow and $3.7M cash balance
- Structural unprofitability with 1.9% gross margin and -$4.1B operating margin relative to revenue
- Minimal quarterly revenue of $105K insufficient to support $78.1M asset base and ongoing operations
- Operating cash flow negative at -$5.1M quarterly indicating business model is not self-sustaining
- Dilution risk from required capital raises or debt financing to extend operational runway
- Business is essentially pre-revenue, so margins and profitability metrics are not economically meaningful yet
- Operating cash flow of -$13.05M versus only $3.91M in cash implies substantial financing risk if commercialization is delayed
- Large recurring operating losses suggest dependence on external capital rather than internally generated cash
Key Metrics to Watch
- Quarterly revenue absolute levels and growth rate toward breakeven sustainability
- Gross margin expansion trajectory as manufacturing scales and product mix improves
- Operating cash flow inflection point toward positive cash generation
- Months of cash runway remaining and timing of next capital raise requirement
- Customer acquisition velocity and average selling prices in surgical robotics market
- Cash runway relative to quarterly operating cash burn
- Sustainable revenue growth from product commercialization rather than one-off or immaterial sales
Microbot Medical Inc. (MBOT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 22.59x current ratio provides a solid financial cushion.
MBOT Profit Margin, ROE & Profitability Analysis
MBOT vs Healthcare Sector: How Microbot Medical Inc. Compares
How Microbot Medical Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Microbot Medical Inc. Stock Overvalued? MBOT Valuation Analysis 2026
Based on fundamental analysis, Microbot Medical Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Microbot Medical Inc. Balance Sheet: MBOT Debt, Cash & Liquidity
MBOT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Microbot Medical Inc.'s revenue has declined by 29% over the 5-year period, indicating business contraction. The most recent EPS of $-0.73 indicates the company is currently unprofitable.
MBOT Revenue Growth, EPS Growth & YoY Performance
MBOT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $105.0K | -$2.6M | $-0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Microbot Medical Inc. Dividends, Buybacks & Capital Allocation
MBOT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Microbot Medical Inc. (CIK: 0000883975)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MBOT
What is the AI rating for MBOT?
Microbot Medical Inc. (MBOT) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MBOT's key strengths?
Claude: Strong balance sheet with $74.1M stockholders equity and 0.03x debt-to-equity ratio. Excellent liquidity position (22.59x current ratio) provides flexibility for immediate needs. ChatGPT: Very low leverage with debt/equity of 0.03x and modest total liabilities relative to equity. Strong reported current and quick ratios, indicating limited near-term balance sheet pressure from liabilities.
What are the risks of investing in MBOT?
Claude: Critical cash runway of less than one quarter given -$5.2M quarterly free cash flow and $3.7M cash balance. Structural unprofitability with 1.9% gross margin and -$4.1B operating margin relative to revenue. ChatGPT: Business is essentially pre-revenue, so margins and profitability metrics are not economically meaningful yet. Operating cash flow of -$13.05M versus only $3.91M in cash implies substantial financing risk if commercialization is delayed.
What is MBOT's revenue and growth?
Microbot Medical Inc. reported revenue of $105.0K.
Does MBOT pay dividends?
Microbot Medical Inc. does not currently pay dividends.
Where can I find MBOT SEC filings?
Official SEC filings for Microbot Medical Inc. (CIK: 0000883975) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MBOT's EPS?
Microbot Medical Inc. has a diluted EPS of $-0.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MBOT a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Microbot Medical Inc. has a SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MBOT stock overvalued or undervalued?
Valuation metrics for MBOT: ROE of -5.0% (sector avg: 15%), net margin of -3,496.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MBOT stock in 2026?
Our dual AI analysis gives Microbot Medical Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MBOT's free cash flow?
Microbot Medical Inc.'s operating cash flow is $-5.1M, with capital expenditures of $108.0K. FCF margin is -4,915.2%.
How does MBOT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,496.2% (avg: 12%), ROE -5.0% (avg: 15%), current ratio 22.59 (avg: 2).